|Home | About | Journals | Submit | Contact Us | Français|
Mutations in POLG1 are an important cause of human mitochondrial disease. We describe a woman who presented with bilateral ptosis and external ophthalmoplegia at 64 years of age. Neurological examination revealed symptoms of diffuse encephalopathy. The symptoms were progressive and at 67 years she was severely cognitively impaired, had severe bilateral ptosis and complete external ophthalmoplegia. Frequent cytochrome c oxidase-negative fibres were detected in muscle. Electrophysiological examination revealed myopathic changes and axonal neuropathy. Standard laboratory tests were normal. Brain CT showed general, moderate cortical atrophy. Molecular analysis of muscle DNA revealed multiple mitochondrial DNA deletions. Sequencing of the entire POLG1 gene revealed two changes c.2993C>T (p.998S>L) and c.3550G>C (p.1184D>H). Both mutations are previously unreported and confirmed to be compound heterozygous. Late-onset progressive external ophthalmoplegia with severe encephalopathy is an unusual combination in patients with POLG1 mutations. POLG-associated disease should be considered in any patient with unexplained or unusual neurological features.
This case represents two novel compound heterozygous mutations of the POLG1 gene causing an uncommon phenotype with adult-onset progressive external ophthalmoplegia (PEO) and progressive encephalopathy as dominant features. The case depicts the clinical symptoms caused by these novel mutations and further confirms that the possibility of a POLG-associated disease should be considered in any patient with unexplained or unusual neurological features.
The patient is a woman with an uneventful medical history until the age of 50 years when she had a breast cancer operation. Axillary lymph node evacuation and postoperative radiation treatment was performed at age 54 years. She also had a history of psychiatric symptoms of unknown quality and she had been on antidepressive medication. Her parents had had no known medical conditions. Her father had died at age 75 years and her mother at age 85 years. The patient was her parents' only child. She had two adult daughters, who were healthy.
At age 64 years she was referred to an ophthalmologist for consideration of surgical treatment of bilateral ptosis. There was no history of diplopia, headache or difficulties with swallowing. At that time, her medication consisted of bisoprolol, losartan, quetiapine and escitalopram. The ophthalmologist confirmed bilateral ptosis, but diagnosed also external ophthalmoplegia. Neurological examination revealed symptoms of diffuse encephalopathy: echolalia, automatic laughter, depression, general cognitive slowness, problems in understanding and following commands in clinical examination, confusion and disorientation, as well as general clumsiness. There were no signs of hemiparesis, tendon reflexes were weak but symmetric and she had flexor plantar responses. The disease history and the clinical assessment were not suggestive of dementia of Alzheimer type. The patient had no history of seizures or other symptoms suggestive of epilepsy. Her Mini-Mental State Examination (MMSE) score at age 64 years was 27 points out of 30, which is decreased but not indicative of dementia. MMSE was not repeated, but later clinical notes indicate definite progression of the cognitive problems leading to dementia at age 67 years. The patient had slowly progressive symmetric limb muscle weakness. She was not able to move unaided and was not able to live independently. She had severe bilateral ptosis and complete external ophthalmoplegia. She died from pneumonia at age 67 years in a nursing home.
Histological examination of a sample from the right vastus lateralis muscle showed abnormally frequent cytochrome c oxidase (COX)-negative fibres at the age of 64 years (figure 1A). Electrophysiological examination revealed myopathic changes and they were most prominent in facial muscles. Furthermore, sensory more than motor axonal neuropathy was observed. Facial nerve conduction was not studied. An aerobic exercise test was not performed. Acetylcholine receptor antibodies were not detected. Fasting blood glucose, transaminase values, creatinine, creatine kinase, thyroid function tests and serum sodium and potassium were normal. Blood pyruvate was 172 µmol/litre (laboratory reference 40–70 µmol/litre); blood lactate was not determined. Cerebrospinal fluid analysis was not performed. Brain CT and MRI showed general cortical atrophy that was not particularly prominent in temporo-parietal structures, and no focal abnormalities. There were no signs of vascular lesions or hydrocephalus. Additional central nervous system examinations were not performed.
Total DNA was extracted from muscle tissue homogenate using the standard sodium dodecyl sulphate-proteinase K method and from blood using QIAamp DNA Blood Mini Kit (Qiagen, Valencia, California, USA). Mitochondrial DNA (mtDNA) deletions were analysed by long PCR (Expand Long Template PCR System kit; Roche, Mannheim, Germany). Blood DNA was used as a template to amplify and sequence the 23 coding exons of the POLG1 gene (NM_002693) in the proband by automated sequencing (ABI PRISM 3100 Genetic Analyzer; Applied Biosystems, Foster City, California, USA) using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) after treatment with exonuclease I and shrimp alkaline phosphatase. The novel sequence variants found in POLG1 were confirmed using restriction fragment length polymorphism analysis. The p.1184D>H substitution destroys a recognition site for TaqI leading to an undigested PCR product of 289 bp in size. The p.998S>L substitution destroys a recognition site for Hpy118I leading to an undigested PCR product of 277 bp in size.
Initial analysis for the common mtDNA point mutations m.3243A>G, m.8344A>G and m.8993T>C, as well as Southern blot analysis to demonstrate large mtDNA deletions, were negative. Further molecular analysis revealed multiple mtDNA deletions confirming mitochondrial disease (figure 1B). Sequencing of the entire POLG1 gene revealed two heterozygous nucleotide substitutions: c.2993C>T (p.998S>L) and c.3550G>C (p.1184D>H) (figure 1C). Both are previously unreported. The two daughters of the proband as well as one child of the elder daughter harboured heterozygous p.1184D>H, but p.998S>L was found only in the proband. These findings confirm that the two novel base exchanges in the proband were heterozygous in trans.
Since 1989, nuclear defects have been implicated as possible aetiologies of mitochondrial disease.1 POLG1 gene encodes the catalytic subunit of pol-γ, the only DNA polymerase in human mitochondria, and its mutations have emerged as an important aetiology of human mitochondrial disease.2–5 PEO and encephalopathy are both frequent phenotypic features in mitochondrial diseases but, in patients with POLG1 mutations, encephalopathic phenotypes present most often in childhood. The combination of adult-onset PEO and encephalopathy is uncommon.5 6
Our patient had a PEO-plus phenotype consisting of bilateral ptosis, external ophthalmoplegia and progressive encephalopathy as dominant features. Muscle histology showed COX-negative fibres that were abnormally frequent to the age of the patient. Molecular genetic analysis revealed multiple mtDNA deletions in muscle and heterozygous in trans mutations p.998S>L and p.1184D>H in the POLG1 gene. Neither of them has been described previously, but another pathogenic mutation, p.1184D>N, has previously been described in the position 1184. The p.1184D>N mutation has been described in trans with the exonuclease domain mutation p.227R>W in children with failure to thrive, mental retardation and hypotonia,7 and in adults with a linker region mutation p.468N>D with PEO and tetraparesis.8 Both p.998S>L and p.1184D>H mutations are located in the polymerase domain of pol-γ in positions that are evolutionarily conserved suggesting that the mutations are pathogenic.
Our patient harboured two novel POLG1 mutations. Her clinical features, a relatively late adult-onset symptom combination of PEO and prominent, dementing, encephalopathy, demonstrate the wide phenotypic variety of the POLG1 mutations. The possibility of a POLG-associated disease should be considered in any patient with unexplained or unusual neurological features.9
The authors thank Ms Anja Heikkinen and Ms Pirjo Keränen for their expert assistance. The work was supported by the Research Council for Health at the Academy of Finland, the Sigrid Juselius Foundation, the National Graduate School of Clinical Investigation (CLIGS) and the North Ostrobothnia Regional Fund of the Finnish Cultural Foundation.
Competing interests None.
Patient consent Obtained.